Core Insights - Cognito Therapeutics completed a $105 million Series C financing round, led by Morningside Ventures, IAG Capital Partners, and Starbloom Capital, with participation from other investors [2] - The company aims to accelerate clinical research, regulatory submissions, and commercialization of its core product, the Spectris non-invasive neuromodulation system, which is expected to enter the market around 2027 [2][4] - The technology focuses on using specific frequencies of light and sound to regulate brain activity, differing from traditional electrical stimulation methods [2][5] Company Overview - Founded in 2016 and based in Cambridge, Massachusetts, Cognito Therapeutics specializes in neuromodulation technology and devices for treating neurodegenerative diseases [4] - The company's technology is based on research from MIT regarding Gamma (γ) brain wave oscillations, which are significantly weakened in Alzheimer's patients [4][8] - The Spectris system aims to restore Gamma oscillations through non-invasive stimulation, with early clinical studies showing promising results [5][7] Industry Context - Alzheimer's disease presents a significant challenge globally, with approximately 55 million dementia patients, 60%-70% of whom have Alzheimer's [8] - Traditional drug treatments have faced challenges regarding efficacy, target populations, and pricing, leading to increased interest in device-based treatment approaches [8][9] - Neuromodulation is emerging as a key direction in the treatment of neurodegenerative diseases, with a shift from invasive to non-invasive therapies [11][12] Investment Trends - The financing of Cognito is part of a broader trend in the neuromodulation sector, with increased capital activity observed in recent years [14] - Investment in neuromodulation technologies is primarily focused on three areas: invasive neural stimulation, transcranial magnetic stimulation (TMS), and non-invasive light and sound stimulation [15] - Compared to general brain-computer interfaces, neuromodulation devices have clearer regulatory pathways and business models, facilitating quicker market entry [16] Implications for the Chinese Market - In China, the development of neuromodulation technology is also progressing, with companies focusing on TMS and neural electrical stimulation devices [19] - However, neuromodulation therapies specifically targeting Alzheimer's disease are still in early stages [20] - Cognito's approach highlights a potential direction for Chinese medical device companies, emphasizing brain rhythm modulation to intervene in neurodegenerative diseases [21][23]